Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Barton, Ann Kristin ^a   Gehlen, Heidrun ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; MATRIX METALLOPROTEINASE; SERUM AMYLOID A; HAPTOGLOBIN;

ASTHMA; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOTAXIS; CHRONIC RESPIRATORY TRACT DISEASE; DISEASE SEVERITY; FIBRINOLYSIS; HORSE DISEASE; LUNG PARENCHYMA; NEUTROPHIL; NONHUMAN; REVIEW; SMOOTH MUSCLE; AIRWAY OBSTRUCTION; AIRWAY REMODELING; ANIMAL; BLOOD CLOTTING; EXTRACELLULAR MATRIX; HORSE; HUMAN; INFLAMMATION; LUNG DISEASE; METABOLISM; PHENOTYPE; SPECIES DIFFERENCE;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ANIMALS; ASTHMA; BLOOD COAGULATION; BRONCHOALVEOLAR LAVAGE FLUID; EXTRACELLULAR MATRIX; HAPTOGLOBINS; HORSE DISEASES; HORSES; HUMANS; INFLAMMATION; LUNG DISEASES; MATRIX METALLOPROTEINASES; NEUTROPHILS; PHENOTYPE; SERUM AMYLOID A PROTEIN; SPECIES SPECIFICITY;

EID: 85008627302     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/5693205     Document Type: Review

References (168)

1. K. J. Allen, W. H. Tremaine, and S. H. Franklin, "Prevalence of inflammatory airway disease in national hunt horses referred for investigation of poor athletic performance," Equine Veterinary Journal. Supplement, no. 36, pp. 529-534, 2006.
2. B. B. Martin Jr., V. B. Reef, E. J. Parente, and A. D. Sage, "Causes of poor performance of horses during training, racing, or showing: 348 cases (1992-1996)," Journal of the American Veterinary Medical Association, vol. 216, no. 4, pp. 554-558, 2000.
3. L. L. Couëtil, J. M. Cardwell, V. Gerber et al., "Inflammatory airway disease of horses-revised consensus statement," Journal of Veterinary Internal Medicine, vol. 30, pp. 503-515, 2016.
4. M. Leclere, A. Lavoie-Lamoureux, and J.-P. Lavoie, "Heaves, an asthma-like disease of horses," Respirology, vol. 16, no. 7, pp. 1027-1046, 2011.
5. M. Bullone and J.-P. Lavoie, "Asthma 'of horses and men'-how can equine heaves help us better understand human asthma immunopathology and its functional consequences?"Molecular Immunology, vol. 66, no. 1, pp. 97-105, 2015.
6. R. S. Pirie, "Recurrent airway obstruction: a review," Equine Veterinary Journal, vol. 46, no. 3, pp. 276-288, 2014.
7. C. Qiu, J. Zhang, M. Su et al., "Nuclear factor-κB mediates the phenotype switching of airway smooth muscle cells in a murine asthma model," International Journal of Clinical and Experimental Pathology, vol. 8, pp. 12115-12128, 2015.
8. K. Nakagome, S. Matsushita, and M. Nagata, "Neutrophilic inflammation in severe asthma," International Archives of Allergy and Immunology, vol. 158, no. 1, pp. 96-102, 2012.
9. S. E. Wenzel, "Asthma phenotypes: the evolution from clinical to molecular approaches," Nature Medicine, vol. 18, no. 5, pp. 716-725, 2012.
10. J. R. Pascoe, G. L. Ferraro, J. H. Cannon, R. M. Arthur, and J. D. Wheat, "Exercise induced pulmonary hemorrhage in racing thoroughbreds: a preliminary study," American Journal of Veterinary Research, vol. 42, no. 5, pp. 703-707, 1981.
11. C. F. Raphel and L. R. Soma, "Exercise-induced pulmonary hemorrhage in Thoroughbreds after racing and breezing," American Journal of Veterinary Research, vol. 43, no. 7, pp. 1123-1127, 1982.
12. J. R. Newton and J. L. Wood, "Evidence of an association between inflammatory airway disease and EIPH in young Thoroughbreds during training," Equine Veterinary Journal. Supplement, no. 34, pp. 417-424, 2002.
13. J. L. N. Wood, J. R. Newton, N. Chanter, and J. A. Mumford, "Association between respiratory disease and bacterial and viral infections in British racehorses," Journal of Clinical Microbiology, vol. 43, no. 1, pp. 120-126, 2005.
14. E. Deegen, "Das chronisch lungenkranke Pferd und sein Einsatz im Sport,"Der Praktische Tierarzt, Colleg Vet XVII: 15-19, 1986.
15. L. Viel, Structural-functional correlations of the lung in the normal light horse [M.S. thesis], University of Guelph, Guelph, Canada, 1980.
16. L. Bjermer, "Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation," Journal of Allergy and Clinical Immunology, vol. 120, no. 6, pp. 1269-1275, 2007.
17. S. R. Rosenberg and R. Kalhan, "Biomarkers in chronic obstructive pulmonary disease," Translational Research, vol. 159, no. 4, pp. 228-237, 2012.
18. A. Koutsokera, D. Stolz, S. Loukides, andK. Kostikas, "Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge," Chest, vol. 141, no. 2, pp. 396-405, 2012.
19. F. J. Derksen, J. S. Scott, D. C. Miller, R. F. Slocombe, and N. E. Robinson, "Bronchoalveolar lavage in ponies with recurrent airway-obstruction (heaves)," American Review of Respiratory Disease, vol. 132, no. 5, pp. 1066-1070, 1985.
20. G. F. Schusser, M. Wiegand, and A. Ruhland, "Technique and cell differential in bronchoalveolar lavage of horseswithCOPD," Der Praktische Tierarzt, vol. 80, no. 7, pp. 601-604, 1999.
21. G. M. Tremblay, C. Ferland, J.M. Lapointe, A. Vrins, J. P. Lavoie, and Y. Cormier, "Effect of stabling on bronchoalveolar cells obtained from normal and COPD horses," Equine Veterinary Journal, vol. 25, no. 3, pp. 194-197, 1993.
22. S. M. Fairbairn, C. P. Page, P. Lees, and F. M. Cunningham, "Early neutrophil but not eosinophil or platelet recruitment to the lungs of allergic horses following antigen exposure," Clinical and Experimental Allergy, vol. 23, no. 10, pp. 821-828, 1993.
23. T. J. Brazil, M. P. Dagleish, B. C. McGorum, P. M. Dixon, C. Haslett, and E. R. Chilvers, "Kinetics of pulmonary neutrophil recruitment and clearance in a natural and spontaneously resolving model of airway inflammation," Clinical and Experimental Allergy, vol. 35, no. 7, pp. 854-865, 2005.
24. M. Franchini, U. Gilli, M. K. Akens, R. V. Fellenberg, and V. Bracher, "The role of neutrophil chemotactic cytokines in the pathogenesis of equine chronic obstructive pulmonary disease (COPD)," Veterinary Immunology and Immunopathology, vol. 66, no. 1, pp. 53-65, 1998.
25. C. E. Lopuhaä, T. A. Out, H. M. Jansen, R. C. Aalberse, and J. S. Van der Zee, "Allergen-induced bronchial inflammation in house dust mite-allergic patients with or without asthma," Clinical and Experimental Allergy, vol. 32, no. 12, pp. 1720-1727, 2002.
26. M. Z. Norzila, K. Fakes, R. L. Henry, J. Simpson, and P. G. Gibson, "Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma," American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 3, pp. 769-774, 2000.
27. C. L. Ordonez, T. E. Shaughnessy, M. A. Matthay, and J. V. Fahy, "Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and biologic significance," American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 4, pp. 1185-1190, 2000.
28. N. E. Robinson, "International workshop on equine chronic airway disease Michigan State University 16-18 June 2000," Equine Veterinary Journal, vol. 33, no. 1, pp. 5-19, 2001.
29. U. Fogarty and T. Buckley, "Bronchoalveolar lavage findings in horses with exercise intolerance," Equine veterinary journal, vol. 23, no. 6, pp. 434-437, 1991.
30. L. L. Couëtil and D. B. Denicola, "Blood gas, plasma lactate and bronchoalveolar lavage cytology analyses in racehorses with respiratory disease," Equine Veterinary Journal, vol. 30, pp. 77-82, 1999.
31. B. R. Moore, S. Krakowka, J. T. Robertson, and J. M. Cummins, "Cytologic evaluation of bronchoalveolar lavage fluid obtained from standardbred racehorses with inflammatory airway disease," American Journal of Veterinary Research, vol. 56, no. 5, pp. 562-567, 1995.
32. S. J. Holcombe, C. Jackson, V. Gerber et al., "Stabling is associated with airway inflammation in young Arabian horses," Equine Veterinary Journal, vol. 33, no. 3, pp. 244-249, 2001.
33. L. L. Couëtil, F. S. Rosenthal, D. B. DeNicola, and C.D. Chilcoat, "Clinical signs, evaluation of bronchoalveolar lavage fluid, and assessment of pulmonary function in horses with inflammatory respiratory disease," American Journal of Veterinary Research, vol. 62, no. 4, pp. 538-546, 2001.
34. A. Sánchez, L. L. Couëtil, M. P. Ward, and S. P. Clark, "Effect of airway disease on blood gas exchange in racehorses," Journal of Veterinary Internal Medicine, vol. 19, no. 1, pp. 87-92, 2005.
35. J. E. Hare, L. Viel, P. M. O'Byrne, and P. D. Conlon, "Effect of sodium cromoglycate on light racehorses with elevated metachromatic cell numbers on bronchoalveolar lavage and reduced exercise tolerance," Journal of Veterinary Pharmacology andTherapeutics, vol. 17, no. 3, pp. 237-244, 1994.
36. A. M. Hoffman, M. R. Mazan, and S. Ellenberg, "Association between bronchoalveolar lavage cytologic features and airway reactivity in horses with a history of exercise intolerance," American Journal of Veterinary Research, vol. 59, no. 2, pp. 176-181, 1998.
37. J. E. Hare and L. Viel, "Pulmonary eosinophilia associated with increased airway responsiveness in young racing horses," Journal of Veterinary Internal Medicine, vol. 12, no. 3, pp. 163-170, 1998.
38. D. M. Ainsworth, G. Grünig, M. B. Matychak et al., "Recurrent airway obstruction (RAO) in horses is characterized by IFN-γ and IL-8 production inbronchoalveolar lavage cells," Veterinary Immunology and Immunopathology, vol. 96, no. 1-2, pp. 83-91, 2003.
39. D. M. Ainsworth, J. A. Appleton, D. F. Antczak, M. A. Santiago, and G. Aviza, "IgG antibody responses to an inhaled antigen in horses with 'heaves' (recurrent airway obstruction)," Veterinary Immunology and Immunopathology, vol. 84, no. 3-4, pp. 169-180, 2002.
40. V. Gerber, N. E. Robinson, P. J. Venta, J. Rawson, A. M. Jefcoat, and J. A. Hotchkiss, "Mucin genes in horse airways: MUC5AC, but not MUC2, may play a role in recurrent airway obstruction," Equine Veterinary Journal, vol. 35, no. 3, pp. 252-257, 2003.
41. A. Lindberg, B. Näsman-Glaser, J. A. Lindgren, and N. E. Robinson, "Evaluation of leukotriene biosynthetic capacity in lung tissues from horses with recurrent airway obstruction," American Journal of Veterinary Research, vol. 63, no. 6, pp. 794-798, 2002.
42. C. A. Jackson, C. Berney, A. M. Jefcoat, and N. E. Robinson, "Environment and prednisone interactions in the treatment of recurrent airway obstruction (heaves)," Equine Veterinary Journal, vol. 32, no. 5, pp. 432-438, 2000.
43. N. E. Robinson, C. A. Jackson, D. Peroni et al., "Why is oral prednisone ineffective for treatment of heaves?" American Association of Equine Practitioners, vol. 46, pp. 266-267, 2000.
44. N.E. Robinson, M. A. Olszewski, D. Boehler et al., "Relationship between clinical signs and lung function in horses with recurrent airway obstruction (heaves) during a bronchodilator trial," Equine Veterinary Journal, vol. 32, no. 5, pp. 393-400, 2000.
45. B.R. Rush, E. S. Raub, M.M. Thomsen, E. G. Davis, C. J. Matson, and J. E. Hakala, "Pulmonary function and adrenal gland suppression with incremental doses of aerosolized beclomethasone dipropionate in horses with recurrent airway obstruction," Journal of the American VeterinaryMedical Association, vol. 217, no. 3, pp. 359-364, 2000.
46. S. L. Henrikson and B. R. Rush, "Efficacy of salmeterol xinafoate in horses with recurrent airway obstruction," Journal of the American Veterinary Medical Association, vol. 218, no. 12, pp. 1961-1965, 2001.
47. J.-P. Lavoie, R. Léguillette, K. Pasloske et al., "Comparison of effects of dexamethasone and the leukotriene D4 receptor antagonist L-708,738 on lung function and airway cytologic findings in horses with recurrent airway obstruction,"American Journal of Veterinary Research, vol. 63, no. 4, pp. 579-585, 2002.
48. R. Léguillette, C. Désévaux, and J.-P. Lavoie, "Effects of pentoxifylline on pulmonary function and results of cytologic examination of bronchoalveolar lavage fluid in horses with recurrent airway obstruction," American Journal of Veterinary Research, vol. 63, no. 3, pp. 459-463, 2002.
49. N. E. Robinson, C. Jackson, A. Jefcoat, C. Berney, D. Peroni, and F. J. Derksen, "Efficacy of three corticosteroids for the treatment of heaves," Equine Veterinary Journal, vol. 34, no. 1, pp. 17-22, 2002.
50. N. E. Robinson, A. M. Jefcoat, and V. Gerber, "Mucus and inflammation in equine heaves," Pferdeheilkunde, vol. 18, no. 6, pp. 551-556, 2002.
51. V. Picandet, R. Léguillette, and J.-P. Lavoie, "Comparison of efficacy and tolerability of isoflupredone and dexamethasone in the treatment of horses affected with recurrent airway obstruction ('heaves')," Equine Veterinary Journal, vol. 35, no. 4, pp. 419-424, 2003.
52. M. R. Mazan, A. M. Hoffman, H. Kuehn, and E. F. Deveney, "Effect of aerosolized albuterol sulfate on resting energy expenditure determined by use of open-flow indirect calorimetry in horses with recurrent airway obstruction," American Journal of Veterinary Research, vol. 64, no. 2, pp. 235-242, 2003.
53. K. J. Rickards, C. P. Page, and F. M. Cunningham, "Allergen challenge alters lymphocyte phosphodiesterase activity in horses with heaves," Pulmonary Pharmacology and Therapeutics, vol. 17, no. 3, pp. 163-172, 2004.
54. J.-P. Lavoie, K. Maghni, M. Desnoyers, R. Taha, J. G. Martin, and Q. A. Hamid, "Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile," American Journal of Respiratory and Critical CareMedicine, vol. 164, no. 8, pp. 1410-1413, 2001.
55. R. E. Beadle, D. W. Horohov, and S. D. Gaunt, "Interleukin-4 and interferon-gamma gene expression in summer pastureassociated obstructive pulmonary disease affected horses," Equine Veterinary Journal, vol. 34, no. 4, pp. 389-394, 2002.
56. M.-E. Cordeau, P. Joubert, O. Dewachi, Q. Hamid, and J.-P. Lavoie, "IL-4, IL-5 and IFN-γ mRNA expression in pulmonary lymphocytes in equine heaves," Veterinary Immunology and Immunopathology, vol. 97, no. 1-2, pp. 87-96, 2004.
57. V. Gerber, J. E. Swinburne, S. C. Blott et al., "Genetics of recurrent airway obstruction (RAO)," Deutsche Tierarztliche Wochenschrift, vol. 115, no. 7, pp. 271-275, 2008.
58. C. Kleiber, B. C. McGorum, D. W. Horohov, R. S. Pirie, A. Zurbriggen, and R. Straub, "Cytokine profiles of peripheral blood and airway CD4 and CD8 T lymphocytes in horses with recurrent airway obstruction," Veterinary Immunology and Immunopathology, vol. 104, no. 1-2, pp. 91-97, 2005.
59. J. Klier, S. Fuchs, A. May et al., "A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses," Pharmaceutical Research, vol. 29, no. 6, pp. 1650-1657, 2012.
60. M. Franchini, U. Gill, R. Von Fellenberg, and V. D. Bracher, "Interleukin-8 concentration and neutrophil chemotactic activity in bronchoalveolar lavage fluid of horses with chronic obstructive pulmonary disease following exposure to hay," American Journal ofVeterinary Research, vol. 61, no. 11, pp. 1369-1374, 2000.
61. M. Debrue, E. Hamilton, P. Joubert, S. Lajoie-Kadoch, and J.-P. Lavoie, "Chronic exacerbation of equine heaves is associated with an increased expression of interleukin-17 mRNA in bronchoalveolar lavage cells," Veterinary Immunology and Immunopathology, vol. 105, no. 1-2, pp. 25-31, 2005.
62. D. M. Ainsworth, B. Wagner, H. N. Erb et al., "Effects of in vitro exposure to hay dust on expression of interleukin-17,-23,-8, and-1β and chemokine (C-X-Cmotif) ligand 2 by pulmonary mononuclear cells isolated from horses chronically affected with recurrent airway disease," American Journal of Veterinary Research, vol. 68, no. 12, pp. 1361-1369, 2007.
63. T. Art, T. Franck, P. Lekeux et al., "Myeloperoxidase concentration in bronchoalveolar lavage fluid from healthy horses and those with recurrent airway obstruction," Canadian Journal of Veterinary Research, vol. 70, no. 4, pp. 291-296, 2006.
64. K. Fey, Der klinische Nutzen Zytologischer Untersuchungen von Broncho-Alveolärer Lavageflüssigkeit bei der Differenzierung Chronischer Bronchitiden des Pferdes, Justus-Liebig-Universität Gießen, Giessen, Germany, 2004.
65. C. M. Deaton, D. J. Marlin, L. Deaton et al., "Comparison of the antioxidant status in tracheal and bronchoalveolar epithelial lining fluids in recurrent airway obstruction," Equine Veterinary Journal, vol. 38, no. 5, pp. 417-422, 2006.
66. C. M. Deaton, "The role of oxidative stress in an equine model of human asthma," Redox Report, vol. 11, no. 2, pp. 46-52, 2006.
67. C. M. Deaton, D. J. Marlin, N. C. Smith et al., "Antioxidant and inflammatory responses of healthy horses and horses affected by recurrent airway obstruction to inhaled ozone," Equine Veterinary Journal, vol. 37, no. 3, pp. 243-249, 2005.
68. C.M. Deaton, D. J. Marlin, N. C. Smith et al., "Effect of acute airway inflammation on the pulmonary antioxidant status," Experimental Lung Research, vol. 31, no. 7, pp. 653-670, 2005.
69. C. M. Deaton, D. J. Marlin, N. C. Smith et al., "Pulmonary epithelial lining fluid and plasma ascorbic acid concentrations in horses affected by recurrent airway obstruction," American Journal of Veterinary Research, vol. 65, no. 1, pp. 80-87, 2004.
70. L. G. Wood, K. J. Baines, J. Fu, H. A. Scott, and P. G. Gibson, "The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma," Chest, vol. 142, no. 1, pp. 86-93, 2012.
71. M. Miskovic, L. L. Couëtil, and C. A. Thompson, "Lung function and airway cytologic profiles in horses with recurrent airway obstruction maintained in low-dust environments," Journal of Veterinary InternalMedicine, vol. 21, no. 5, pp. 1060-1066, 2007.
72. C. Sandersen, F. Bureau, R. Turlej et al., "p65 Homodimer activity in distal airway cells determines lung dysfunction in equine heaves," Veterinary Immunology and Immunopathology, vol. 80, no. 3-4, pp. 315-326, 2001.
73. A. Lavoie-Lamoureux, K. Moran, G. Beauchamp et al., "IL-4 activates equine neutrophils and induces a mixed inflammatory cytokine expression profile with enhanced neutrophil chemotactic mediator release ex vivo," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 299, no. 4, pp. L472-L482, 2010.
74. K. J. Rickards, C. P. Page, P. Lees, G. Gettinby, and F. M. Cunningham, "In vitro and ex vivo effects of the phosphodiesterase 4 inhibitor, rolipram, on thromboxane production in equine blood," Journal of Veterinary Pharmacology and Therapeutics, vol. 26, no. 2, pp. 123-130, 2003.
75. K. A. Marr, P. Lees, and F. M. Cunningham, "Antigen challenge increases adherence of circulating neutrophils in horses with chronic obstructive pulmonary disease," Equine Veterinary Journal, vol. 34, no. 1, pp. 65-70, 2002.
76. N. Kirschvink, N. Smith, L. Fiévez et al., "Effect of chronic airway inflammation and exercise on pulmonary and systemic antioxidant status of healthy and heaves-affected horses," Equine Veterinary Journal, vol. 34, no. 6, pp. 563-571, 2002.
77. P. R. Gray, F. J. Derksen, N. E. Robinson, L. J. Carpenter-Deyo, H. G. Johnson, and R. A. Roth, "The role of cyclooxygenase products in the acute airway obstruction and airway hyperreactivity of ponies with heaves," American Review of Respiratory Disease, vol. 140, no. 1, pp. 154-160, 1989.
78. S. Kasayama, M. Tanemura, M. Koga, K. Fujita, H. Yamamoto, and A. Miyatake, "Asthma is an independent risk for elevation of plasma C-reactive protein levels," Clinica Chimica Acta, vol. 399, no. 1-2, pp. 79-82, 2009.
79. Y. Y. Koh, Y. W. Kim, J. D. Park, and J. W. Oh, "A comparison of serum haptoglobin levels between acute exacerbation and clinical remission in asthma," Clinical and Experimental Allergy, vol. 26, no. 10, pp. 1202-1209, 1996.
80. T.-L. Wu, P.-Y. Chang, K.-C. Tsao, C.-F. Sun, L. L. Wu, and J. T. Wu, "A panel of multiple markers associated with chronic systemic inflammation and the risk of atherogenesis is detectable in asthma and chronic obstructive pulmonary disease," Journal of Clinical Laboratory Analysis, vol. 21, no. 6, pp. 367-371, 2007.
81. J. G. Schanen, C. Iribarren, E. Shahar et al., "Asthma and incident cardiovascular disease: The Atherosclerosis Risk In Communities Study," Thorax, vol. 60, no. 8, pp. 633-638, 2005.
82. Y. Song, A. Klevak, J. E. Manson, J. E. Buring, and S. Liu, "Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study," Diabetes Research and Clinical Practice, vol. 90, no. 3, pp. 365-371, 2010.
83. D. D. Sin, N. R. Anthonisen, J. B. Soriano, and A. G. Agusti, "Mortality in COPD: role of comorbidities," European Respiratory Journal, vol. 28, no. 6, pp. 1245-1257, 2006.
84. S. Yende, G. W. Waterer, E. A. Tolley et al., "Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects," Thorax, vol. 61, no. 1, pp. 10-16, 2006.
85. A. Lavoie-Lamoureux, M. Leclere, K. Lemos, B. Wagner, and J.-P. Lavoie, "Markers of systemic inflammation in horses with heaves," Journal of Veterinary Internal Medicine, vol. 26, no. 6, pp. 1419-1426, 2012.
86. A. Lavoie-Lamoureux, G. Beauchamp, S. Quessy, J. G. Martin, and J.-P. Lavoie, "Systemic inflammation and priming of peripheral blood leukocytes persist during clinical remission in horses with heaves," Veterinary Immunology and Immunopathology, vol. 146, no. 1, pp. 35-45, 2012.
87. A. Niedźwiedź, J. Nicpón, H. Borowicz, P. Llós, M. Zawadzki, and L. Januszewska, "Evaluation of selected antioxidant enzymes in the blood of horses with recurrent airways obstruction," Medycyna Weterynaryjna, vol. 67, no. 2, pp. 129-132, 2011.
88. B. Müller, J. C. White, E. S. Nylén, R.H. Snider, K. L. Becker, and J. F. Habener, "Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis," The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 1, pp. 396-404, 2001.
89. J. M. Pereira, A. Teixeira-Pinto, C. Basílio, C. Sousa-Dias, P. Mergulhão, and J. A. Paiva, "Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?" Journal of Critical Care, vol. 28, no. 6, pp. 970-974, 2013.
90. A. Julián-Jiménez, J. Timón Zapata, E. J. Laserna Mendieta et al., "Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department," Enfermedades Infecciosas y Microbiología Clínica, vol. 32, no. 4, pp. 225-235, 2014.
91. P. Berg and B. O. Lindhardt, "The role of procalcitonin in adult patients with community-acquired pneumonia-a systematic review," DanishMedical Journal, vol. 59, no. 3, Article IDA4357, 2012.
92. W. Niu, Y.-G. Wan, M.-Y. Li, Z.-X. Wu, L.-G. Zhang, and J.-X. Wang, "The diagnostic value of serum procalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosis," European Review for Medical and Pharmacological Sciences, vol. 17, no. 24, pp. 3329-3333, 2013.
93. J. Tang, W. Long, L. Yan et al., "Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial," BMC Infectious Diseases, vol. 13, no. article 596, 2013.
94. E. E. Walsh, A. J. Swinburne, K. L. Becker et al., "Can serumprocalcitonin levels help interpret indeterminate chest radiographs in patients hospitalized with acute respiratory illness?" Journal of Hospital Medicine, vol. 8, no. 2, pp. 61-67, 2013.
95. C. E. Brightling, "Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease," Annals of the AmericanThoracic Society, vol. 10, supplement, pp. S214-S219, 2013.
96. Y.-F. Zhao, Y.-P. Jiang, L.-F. Zhou, and X.-L. Wu, "The value of assessment tests in patients with acute exacerbation of chronic obstructive pulmonary disease," American Journal of the Medical Sciences, vol. 347, no. 5, pp. 393-399, 2014.
97. M. Rieger, C. Kochleus, D. Teschner et al., "A new ELISA for the quantification of equine procalcitonin in plasma as potential inflammation biomarker in horses," Analytical and Bioanalytical Chemistry, vol. 406, no. 22, pp. 5507-5512, 2014.
98. D. Teschner, M. Rieger, C. Koopmann, and H. Gehlen, "Procalcitonin in horses with an acute colic," Pferdeheilkunde, vol. 31, no. 4, pp. 371-377, 2015.
99. F. Bonelli, V. Meucci, T. J. Divers et al., "Plasma procalcitonin concentration in healthy horses and horses affected by systemic inflammatory response syndrome," Journal of Veterinary Internal Medicine, vol. 29, no. 6, pp. 1689-1691, 2015.
100. A. Barton, T. Shety, A. Pelli et al., "Evaluation of inflammatory markers and treatment success in inflammatory airway disease under the course of inhalation therapy and environmental dust reduction," in Proceedings of the 2nd Havemeyer Workshop on IAD, Cabourg, France, 2014.
101. D. M. Ainsworth, "Review of recurrent airway obstruction (RAO, Heaves): diagnosis and treatment options," in Proceedings of the AAEP Focus on Upper and Lower Respiratory Diseases 2010, Salt Lake City , Utah, USA, 2010.
102. J. P. Lavoie and B. J. Martin, "Lung remodeling in the horse with heaves," in Proceedings of the Third World Equine Airways Symposium, M. Ainsworth and R. Viel, Eds., Document No. P2114.0705, International Veterinary Information Service, Ithaca, NY, USA, 2005 http://www.ivis.org/.
103. F. J. Kaup, W. Drommer, and E. Deegen, "Ultrastructural findings in horses with chronic obstructive pulmonary disease (COPD) I: alterations of the larger conducting airways," Equine Veterinary Journal, vol. 22, no. 5, pp. 343-348, 1990.
104. F. J. Kaup, W. Drommer, S. Damsch, and E. Deegen, "Ultrastructural findings in horses with chronic obstructive pulmonary disease (COPD) II: pathomorphological changes of the terminal airways and the alveolar region," Equine Veterinary Journal, vol. 22, no. 5, pp. 349-355, 1990.
105. W. Seeger, G. Stohr, H. R. D. Wolf, and H. Neuhof, "Alteration of surfactant function due to protein leakage: special interaction with fibrinmonomer," Journal of Applied Physiology, vol. 58, no. 2, pp. 326-338, 1985.
106. A. Günther, P. Mosavi, S. Heinemann et al., "Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: comparison with the acute respiratory distress syndrome," American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, pp. 454-462, 2000.
107. M. E. Akinnusi and A. A. El Solh, "The role of coagulation in pulmonary pathology," Inflammation and Allergy-Drug Targets, vol. 6, no. 4, pp. 201-209, 2007.
108. B. Nakstad, T. Lyberg, O.H. Skjønsberg, and N. P. Boye, "Local activation of the coagulation and fibrinolysis systems in lung disease," Thrombosis Research, vol. 57, no. 6, pp. 827-838, 1990.
109. S. Idell, "Coagulation, fibrinolysis, and fibrin deposition in acute lung injury," Critical CareMedicine, vol. 31, no. 4, pp. S213-S220, 2003.
110. P. S. Ciano, R. B. Colvin, A. M. Dvorak, and J. McDonagh, "Macrophage migration in fibrin gel matrices," Laboratory Investigation, vol. 54, no. 1, pp. 62-70, 1986.
111. K. J. Leavell, M.W. Peterson, and T. J. Gross, "The role of fibrin degradation products in neutrophil recruitment to the lung," American Journal of Respiratory Cell andMolecular Biology, vol. 14, no. 1, pp. 53-60, 1996.
112. F. Grinnell, M. Feld, and D. Minter, "Fibroblast adhesion to fibrinogen and fibrin substrata: requirement for cold-insoluble globulin (plasma fibronectin)," Cell, vol. 19, no. 2, pp. 517-525, 1980.
113. A. J. Gray, J. E. Bishop, J. T. Reeves, R. P. Mecham, and G. J. Laurent, "Partially degraded fibrin(ogen) stimulates fibroblast proliferation in vitro," American Journal of Respiratory Cell and Molecular Biology, vol. 12, no. 6, pp. 684-690, 1995.
114. R. G. Sitrin, P. M. Pan, S. Srikanth, and R. F. Todd III, "Fibrinogen activates NF-κB transcription factors in mononuclear phagocytes,"TheJournal of Immunology, vol. 161, no. 3, pp. 1462-1470, 1998.
115. W. Seeger, A. Elssner, A. Günther, H.-J. Krämer, and H. O. Kalinowski, "Lung surfactant phospholipids associate with polymerizing fibrin: loss of surface activity," American journal of respiratory cell and molecular biology, vol. 9, no. 2, pp. 213-220, 1993.
116. L. B. Ware, J. A. Bastarache, and L. Wang, "Coagulation and fibrinolysis in human acute lung injury-new therapeutic targets?" Keio Journal of Medicine, vol. 54, no. 3, pp. 142-149, 2005.
117. M. Schuliga, S. G. Royce, S. Langenbach et al., "The coagulant factor Xa induces protease-activated receptor-1 and annexin A2-dependent airway smooth muscle cytokine production and cell proliferation," American Journal of Respiratory Cell and Molecular Biology, vol. 54, no. 2, pp. 200-209, 2016.
118. N. C. Winder, G. Grünig, M. Hermann, and R. von Fellenberg, "Fibrin/fibrinogen in lungs and respiratory secretions of horses with chronic pulmonary disease," American Journal of Veterinary Research, vol. 51, no. 6, pp. 945-949, 1990.
119. M. A. Delgado, L. Monreal, L. Armengou, J. Ríos, andD. Segura, "Peritoneal D-dimer concentration for assessing peritoneal fibrinolytic activity in horses with colic," Journal of Veterinary Internal Medicine, vol. 23, no. 4, pp. 882-889, 2009.
120. L. Monreal, A. Anglés, Y. Espada et al., "Hypercoagulation and hypofibrinolysis in horses with colic and DIC," Equine Veterinary Journal, vol. 32, pp. 19-25, 2000.
121. T. Ribera, L. Monreal, L. Armengou, J. Ríos, and M. Prades, "Synovial fluid D-dimer concentration in foals with septic joint disease," Journal of Veterinary Internal Medicine, vol. 25, no. 5, pp. 1113-1117, 2011.
122. A. L. Clutterbuck, P. Harris, D. Allaway, and A. Mobasheri, "Matrix metalloproteinases in inflammatory pathologies of the horse," Veterinary Journal, vol. 183, no. 1, pp. 27-38, 2010.
123. S. E. Dunsmore and D. E. Rannels, "Extracellular matrix biology in the lung," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 270, no. 1, pp. L3-L27, 1996.
124. S. D. Shapiro, S. K. Endicott, M. A. Province, J. A. Pierce, and E. J. Campbell, "Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon," The Journal of Clinical Investigation, vol. 87, no. 5, pp. 1828-1834, 1991.
125. R. F. Foronjy, Y. Okada, R. Cole, and J. D'Armiento, "Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung," American Journal of Physiology-Lung Cellular andMolecular Physiology, vol. 284, no. 5, pp. L727-L737, 2003.
126. S. D. Shapiro, E. J. Campbell, H. G. Welgus, and R.M. Senior, "Elastin degradation bymononuclear phagocytes," Annals of the New York Academy of Sciences, vol. 624, pp. 69-80, 1991.
127. J. Gross and C. M. Lapiere, "Collagenolytic activity in amphibian tissues: a tissue culture assay," Proceedings of the National Academy of Sciences of the United States of America, vol. 48, pp. 1014-1022, 1962.
128. F. Ratjen, C.-M. Hartog, K. Paul, J. Wermelt, and J. Braun, "Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and theirmodulation by treatment with dornase alpha," Thorax, vol. 57, no. 11, pp. 930-934, 2002.
129. S. Krizkova, O. Zitka, M. Masarik et al., "Clinical importance of matrix metalloproteinases," Bratislava Medical Journal, vol. 112, no. 8, pp. 435-440, 2011.
130. Y. Naito and T. Yoshikawa, "Role of matrix metalloproteinases in inflammatory bowel disease," Molecular Aspects of Medicine, vol. 26, no. 4-5, pp. 379-390, 2005.
131. C. E. Brinckerhoff and L. M. Matrisian, "Matrix metalloproteinases: a tail of a frog that became a prince," Nature Reviews Molecular Cell Biology, vol. 3, no. 3, pp. 207-214, 2002.
132. W. C. Parks, C. L. Wilson, and Y. S. López-Boado, "Matrix metalloproteinases as modulators of inflammation and innate immunity," Nature Reviews Immunology, vol. 4, no. 8, pp. 617-629, 2004.
133. J. J. Atkinson, B. A. Lutey, Y. Suzuki et al., "The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema," American Journal of Respiratory and Critical CareMedicine, vol. 183, no. 7, pp. 876-884, 2011.
134. R. E. K. Russell, S. V. Culpitt, C. DeMatos et al., "Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease," American Journal of Respiratory Cell andMolecular Biology, vol. 26, no. 5, pp. 602-609, 2002.
135. G. A. Finlay, K. J. Russell, K. J. McMahon et al., "Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients," Thorax, vol. 52, no. 6, pp. 502-506, 1997.
136. G. A. Finlay, L. R. O'Driscoll, K. J. Russell et al., "Matrixmetalloproteinase expression and production by alveolar macrophages in emphysema," American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 1, pp. 240-247, 1997.
137. A.-L. Koivunen, P. Maisi, Y. T. Konttinen, and M. Sandholm, "Gelatinolytic activity in tracheal aspirates of horses with chronic obstructive pulmonary disease," Acta Veterinaria Scandinavica, vol. 38, no. 1, pp. 17-27, 1997.
138. A. K. Barton, T. Shety, A. Bondzio, R. Einspanier, and H. Gehlen, "Metalloproteinases and their tissue inhibitors in comparison between different chronic pneumopathies in the horse," Mediators of Inflammation, vol. 2015, Article ID569512, 9 pages, 2015.
139. M. Nevalainen, S. M. Raulo, T. J. Brazil et al., "Inhalation of organic dusts and lipopolysaccharide increases gelatinolytic matrix metalloproteinases (MMPs) in the lungs of heaves horses," Equine Veterinary Journal, vol. 34, no. 2, pp. 150-155, 2002.
140. T. Simonen-Jokinen, R. S. Pirie, B. C. McGorum, and P. Maisi, "Effect of composition and different fractions of hay dust suspension on inflammation in lungs of heaves-affected horses: MMP-9 and MMP-2 as indicators of tissue destruction," Equine Veterinary Journal, vol. 37, no. 5, pp. 412-417, 2005.
141. T. Simonen-Jokinen, R. S. Pirie, B. McGorum, and P. Maisi, "Dose responses to inhalation of endotoxin, hay dust suspension and Aspergillus fumigatus extract in horses as measured by levels and activation of matrix metalloproteinase-9," Equine Veterinary Journal, vol. 37, no. 2, pp. 155-160, 2005.
142. A. Barton, T. Shety, A. Bondzio et al., Changes inMMP-2, MMP-9 and IL-8 in BALF of RAO Horses before and after Therapy, Congress of the European College of Equine InternalMedicine, Le Touquet, France, 2013.
143. A.-L. Koivunen, P. Maisi, Y. T. Konttinen, K. Prikk, and M. Sandholm, "Collagenolytic activity and its sensitivity to doxycycline inhibition in tracheal aspirates of horses with chronic obstructive pulmonary disease," Acta Veterinaria Scandinavica, vol. 38, no. 1, pp. 9-16, 1997.
144. S.M. Raulo, T. Sorsa, T. Tervahartiala et al., "MMP-9asamarker of inflammation in tracheal epithelial lining fluid (TELF) and in bronchoalveolar fluid (BALF) of COPD horses," Equine Veterinary Journal, vol. 33, no. 2, pp. 128-136, 2001.
145. S. M. Raulo, T. A. Sorsa, M. T. Kiili, and P. S. Maisi, "Evaluation of collagenase activity, matrix metalloproteinase-8, and matrix metalloproteinase-13 in horses with chronic obstructive pulmonary disease," American Journal of Veterinary Research, vol. 62, no. 7, pp. 1142-1148, 2001.
146. P. T. G. Elkington and J. S. Friedland, "Matrix metalloproteinases in destructive pulmonary pathology," Thorax, vol. 61, no. 3, pp. 259-266, 2006.
147. D. Bourboulia and W. G. Stetler-Stevenson, "Matrix metalloproteinases (MMPs) and tissue inhibitors ofmetalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion," Seminars in Cancer Biology, vol. 20, no. 3, pp. 161-168, 2010.
148. K. Brew and H. Nagase, "The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1803, no. 1, pp. 55-71, 2010.
149. C. A. Ugarte-Gil, P. Elkington, R. H. Gilman et al., "Induced sputum MMP-1,-3 &-8 concentrations during treatment of tuberculosis," PLoS ONE, vol. 8, Article IDe61333, 2013.
150. J. M. D'Armiento, M. P. Goldklang, A. A. Hardigan et al., "Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema," PLoS ONE, vol. 8, no. 2, Article ID e56352, 2013.
151. S. Oka, H. Furukawa, K. Shimada et al., "Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease," BMC Immunology, vol. 14, no. 1, article no. 9, 2013.
152. R.V. Broadstone, P. H. LeBlanc, F. J. Derksen, andN. E. Robinson, "In vitro responses of airway smooth muscle from horses with recurrent airway obstruction," Pulmonary Pharmacology, vol. 4, no. 4, pp. 191-202, 1991.
153. M. Leclere, A. Lavoie-Lamoureux, E. Gélinas-Lymburner, F. David, J. G. Martin, and J.-P. Lavoie, "Effect of antigenic exposure on airway smooth muscle remodeling in an equine model of chronic asthma," American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 1, pp. 181-187, 2011.
154. M. Leclere, A. Lavoie-Lamoureux, P. Joubert et al., "Corticosteroids and antigen avoidance decrease airway smooth muscle mass in an equine asthma model," American Journal of Respiratory Cell and Molecular Biology, vol. 47, no. 5, pp. 589-596, 2012.
155. M. Leclere, A. Lavoie-Lamoureux, P. Joubert et al., "Corticosteroids and antigen avoidance decrease airway smooth muscle mass in an equine asthma model," American Journal of Respiratory Cell and Molecular Biology, vol. 47, no. 5, pp. 589-596, 2012.
156. B. Yeganeh, C. Xia, H. Movassagh et al., "Emerging mediators of airway smooth muscle dysfunction in asthma," Pulmonary Pharmacology andTherapeutics, vol. 26, no. 1, pp. 105-111, 2013.
157. G. Jarai, M. Sukkar, S. Garrett et al., "Effects of interleukin-1β, interleukin-13 and transforming growth factor-β on gene expression in human airway smooth muscle using gene microarrays," European Journal of Pharmacology, vol. 497, no. 3, pp. 255-265, 2004.
158. R. Issa, S. Xie, K. Y. Lee et al., " GRO-β regulation in airway smooth muscle by IL-1α and TNF-κ: role of NF-βB andMAP kinases," American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 291, no. 1, pp. L66-L74, 2006.
159. S. Sergejeva, S. Ivanov, J. Lotvall, and A. Lindén, "Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation," American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 3, pp. 248-253, 2005.
160. L. Roussel, F. Houle, C. Chan et al., "IL-17 promotes p38MAPKdependent endothelial activation enhancing neutrophil recruitment to sites of inflammation,"The Journal of Immunology, vol. 184, no. 8, pp. 4531-4537, 2010.
161. O. Prause, S. Bozinovski, G. P. Anderson, and A. Lindén, "Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17 in mouse airways," Thorax, vol. 59, no. 4, pp. 313-317, 2004.
162. A. Lindén, "Role of interleukin-17 and the neutrophil in asthma," International Archives of Allergy and Immunology, vol. 126, no. 3, pp. 179-184, 2001.
163. D. M. Ainsworth, B. Wagner, M. Franchini, G. Grünig, H. N. Erb, and J.-Y. Tan, "Time-dependent alterations in gene expression of interleukin-8 in the bronchial epithelium of horses with recurrent airway obstruction," American Journal of Veterinary Research, vol. 67, no. 4, pp. 669-677, 2006.
164. E. Padoan, S. Ferraresso, S. Pegolo, M. Castagnaro, C. Barnini, and L. Bargelloni, "Real time RT-PCR analysis of inflammatory mediator expression in recurrent airway obstruction-affected horses," Veterinary Immunology and Immunopathology, vol. 156, no. 3-4, pp. 190-199, 2013.
165. A. Linden and B. Dahlen, "Interleukin-17 cytokine signalling in patients withasthma," European Respiratory Journal, vol. 44, no. 5, pp. 1319-1331, 2014.
166. A. L. Kolodkin, D. J. Matthes, and C. S. Goodman, "The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules," Cell, vol. 75, no. 7, pp. 1389-1399, 1993.
167. S. Al-Muhsen, J. R. Johnson, and Q. Hamid, "Remodeling in asthma," Journal of Allergy and Clinical Immunology, vol. 128, no. 3, pp. 451-462, 2011.
168. Y. Gan, R. Reilkoff, X. Peng et al., "Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease," Arthritis and Rheumatism, vol. 63, no. 8, pp. 2484-2494, 2011.